Top

Clinical Pharmacokinetics

Published in:

01-12-2012 | Review Article

Population Pharmacokinetic Analysis during the First 2 Years of Life

An Overview

Authors: Amélie Marsot, Audrey Boulamery, Bernard Bruguerolle, Nicolas Simon

Published in: Clinical Pharmacokinetics | Issue 12/2012

Abstract

Three decades after its introduction, pharmacokinetic population approaches have become a reference method for drug modelling, particularly in paediatrics. The main practical limitation in this specific population is the collected blood volume. Pharmacokinetic population approaches using sparse sampling may resolve this issue. The pharmacokinetics of many drugs have been studied during the last 25 years using such methods. This review summarizes all of the published studies concerning population pharmacokinetic approaches in paediatric subjects from neonate to 2 years old. A literature search was conducted using the PubMed database, from 1985 to December 2010, using the following terms: pharmacokinetic(s), population, paediatric/pediatric and neonate(s). Articles were excluded if they were not pertinent according to our criteria. References of all relevant articles were also evaluated. Ninety-eight studies were included in this review. The following information was extracted from the articles: drug name, therapeutic class, population size, age of patients, number of samples per patient, covariates used for clearance and volume of distribution estimates, software used for modelling and validation methods. An increasing rate of publications over the years was observed; 44 different drugs were studied using a pharmacokinetic population approach. Antibacterials were the most studied class of drugs, including a large number of studies devoted to vancomycin and gentamicin. It must be underlined that few studies have been performed on anticonvulsant drugs and anaesthetics used in clinical daily practice conditions.

Steinbrook R. Testing medications in children. N Engl J Med. 2002;347:1462–70.PubMedCrossRef

Rosato J. The ethics of clinical trials: a child’s view. J Law Med Ethics. 2000;28:362–78.PubMedCrossRef

Conroy S, Choonara I, Impicciatore P, et al. Survey of unlicensed and off label drug use in paediatric wards in European countries. BMJ. 2000;320:79–82.PubMedPubMedCentralCrossRef

Treluyer JM, Berger JF, Leclerc F, et al. Use of off-label and unlicensed drugs in neonatal and paediatric intensive care in France [abstract no. 46A]. Pediatric Academic Societies Annual Meeting; 1–4 May 1999; San Francisco.

Chalumeau M, Treluyer JM, Salenave B, et al. Off label and unlicensed drug use among office-based paediatricians. Arch Dis Child. 2000;82:502–5.CrossRef

Anderson GD, Lynn AM. Optimizing pediatric dosing: a developmental pharmacologic approach. Pharmacotherapy. 2009;29(6):680–90.PubMedCrossRef

Anderson BJ. My child is unique; the pharmacokinetics are universal. Paediatr Anaesth. 2012;22(6):530–8.PubMedCrossRef

Brendel K, Dartois C, Comets E, Lemenuel-Diot A, Laveille C, Tranchand B, et al. Are population pharmacokinetic and/or pharmacodynamic models adequately evaluated? A survey of the literature from 2002 to 2004. Clin Pharmacokinet. 2007;46(3):221–34.PubMedPubMedCentralCrossRef

Tod M, Jullien V, Pons G. Facilitation of drug evaluation in children by population methods and modelling. Clin Pharmacokinet. 2008;47(4):231–43.PubMedCrossRef

10.

Grasela TH Jr, Donn SM. Neonatal population pharmacokinetics of phenobarbital derived from routine clinical data. Dev Pharmacol Ther. 1985;8(6):374–83.PubMed

11.

Schaible DH, Rocci ML Jr, Alpert GA, Campos JM, Paul MH, Polin RA, et al. Vancomycin pharmacokinetics in infants: relationships to indices of maturation. Pediatr Infect Dis. 1986;5(3):304–8.PubMedCrossRef

12.

Thomson AH, Way S, Bryson SM, McGovern EM, Kelman AW, Whiting B. Population pharmacokinetics of gentamicin in neonates. Dev Pharmacol Ther. 1988;11(3):173–9.PubMed

13.

Moore ES, Faix RG, Banagale RC, Grasela TH. The population pharmacokinetics of theophylline in neonates and young infants. J Pharmacokinet Biopharm. 1989;17(1):47–66.PubMedCrossRef

14.

Wiest DB, Pinson JB, Gal PS, Brundage RC, Schall S, Ransom JL, et al. Population pharmacokinetics of intravenous indomethacin in neonates with symptomatic patent ductus arteriosus. Clin Pharmacol Ther. 1991;49(5):550–7.PubMedCrossRef

15.

Karlsson MO, Thomson AH, McGovern EM, Chow P, Evans TJ, Kelman AW. Population pharmacokinetics of rectal theophylline in neonates. Ther Drug Monit. 1991;13(3):195–200.PubMedCrossRef

16.

Fattinger K, Vozeh S, Olafsson A, Vlcek J, Wenk M, Follath F. Netilmicin in the neonate: population pharmacokinetic analysis and dosing recommendations. Clin Pharmacol Ther. 1991;50(1):55–65.PubMedCrossRef

17.

Izquierdo M, Lanao JM, Cervero L, Jimenez NV, Domínguez-Gil A. Population pharmacokinetics of gentamicin in premature infants. Ther Drug Monit. 1992;14(3):177–83.PubMedCrossRef

18.

Jensen PD, Edgren BE, Brundage RC. Population pharmacokinetics of gentamicin in neonates using a nonlinear, mixed-effects model. Pharmacotherapy. 1992;12(3):178–82.PubMed

19.

Karna P, Lee C, Kumar A, Dyke J, Gooch WM 3rd. Population pharmacokinetics of ceftizoxime in premature newborns. Dev Pharmacol Ther. 1993;20(3–4):135–43.PubMed

20.

Weber W, Kewitz G, Rost KL, Looby M, Nitz M, Harnisch L. Population kinetics of gentamicin in neonates. Eur J Clin Pharmacol. 1993;44(Suppl 1):S23–5.PubMedCrossRef

21.

Asbury WH, Darsey EH, Rose WB, Murphy JE, Buffington DE, Capers CC. Vancomycin pharmacokinetics in neonates and infants: a retrospective evaluation. Ann Pharmacother. 1993;27(4):490–6.PubMedCrossRef

22.

Burtin P, Jacqz-Aigrain E, Girard P, Lenclen R, Magny JF, Betremieux P, et al. Population pharmacokinetics of midazolam in neonates. Clin Pharmacol Ther. 1994;56(6 Pt 1):615–25.PubMedCrossRef

23.

Seay RE, Brundage RC, Jensen PD, Schilling CG, Edgren BE. Population pharmacokinetics of vancomycin in neonates. Clin Pharmacol Ther. 1994;56(2):169–75.PubMedCrossRef

24.

Lee TC, Charles BG, Steer PA, Flenady VJ, Grant TC. Theophylline population pharmacokinetics from routine monitoring data in very premature infants with apnoea. Br J Clin Pharmacol. 1996;41(3):191–200.PubMedCrossRef

25.

Zhou XJ, Gruber W, Demmler G, Jacobs R, Reuman P, Adler S, et al. Population pharmacokinetics of ganciclovir in newborns with congenital cytomegalovirus infections: NIAID Collaborative Antiviral Study Group. Antimicrob Agents Chemother. 1996;40(9):2202–5.PubMedPubMedCentral

26.

Thomson AH, Kerr S, Wright S. Population pharmacokinetics of caffeine in neonates and young infants. Ther Drug Monit. 1996;18(3):245–53.PubMedCrossRef

27.

Harte GJ, Gray PH, Lee TC, Steer PA, Charles BG. Haemodynamic responses and population pharmacokinetics of midazolam following administration to ventilated, preterm neonates. J Paediatr Child Health. 1997;33(4):335–8.PubMedCrossRef

28.

Charles BG, Preechagoon Y, Lee TC, Steer PA, Flenady VJ, Debuse N. Population pharmacokinetics of intravenous amoxicillin in very low birth weight infants. J Pharm Sci. 1997;86(11):1288–92.PubMedCrossRef

29.

de Hoog M, Schoemaker RC, Mouton JW, van den Anker JN. Tobramycin population pharmacokinetics in neonates. Clin Pharmacol Ther. 1997;62(4):392–9.PubMedCrossRef

30.

Falcão AC, de Fernández Gatta MM, Delgado Iribarnegaray MF, Santos Buelga D, García MJ, Dominguez-Gil A, et al. Population pharmacokinetics of caffeine in premature neonates. Eur J Clin Pharmacol. 1997;52(3):211–7.PubMedCrossRef

31.

Lee TC, Charles B, Steer P, Flenady V, Shearman A. Population pharmacokinetics of intravenous caffeine in neonates with apnea of prematurity. Clin Pharmacol Ther. 1997;61(6):628–40.PubMedCrossRef

32.

Botha JH, du Preez MJ, Miller R, Adhikari M. Determination of population pharmacokinetic parameters for amikacin in neonates using mixed-effect models. Eur J Clin Pharmacol. 1998;53(5):337–41.PubMedCrossRef

33.

Yasuhara M, Iga T, Zenda H, Okumura K, Oguma T, Yano Y, Hori R. Population pharmacokinetics of vancomycin in Japanese pediatric patients. Ther Drug Monit. 1998;20(6):612–8.PubMedCrossRef

34.

Silva R, Reis E, Bispo MA, Almeida AM, Costa IM, Falcão F, et al. The kinetic profile of vancomycin in neonates. J Pharm Pharmacol. 1998;50(11):1255–60.PubMedCrossRef

35.

Lee TC, Charles BG, Harte GJ, Gray PH, Steer PA, Flenady VJ. Population pharmacokinetic modeling in very premature infants receiving midazolam during mechanical ventilation: midazolam neonatal pharmacokinetics. Anesthesiology. 1999;90(2):451–7.PubMedCrossRef

36.

du Preez MJ, Botha JH, McFadyen ML, Holford NH. The pharmacokinetics of theophylline in premature neonates during the first few days after birth. Ther Drug Monit. 1999;21(6):598–603.PubMedCrossRef

37.

Vervelde ML, Rademaker CM, Krediet TG, Fleer A, van Asten P, van Dijk A. Population pharmacokinetics of gentamicin in preterm neonates: evaluation of a once-daily dosage regimen. Ther Drug Monit. 1999;21(5):514–9.PubMedCrossRef

38.

Grimsley C, Thomson AH. Pharmacokinetics and dose requirements of vancomycin in neonates. Arch Dis Child Fetal Neonatal Ed. 1999;81(3):F221–7.PubMedPubMedCentralCrossRef

39.

Preechagoon Y, Charles B, Piotrovskij V, Donovan T, Van Peer A. Population pharmacokinetics of enterally administered cisapride in young infants with gastro-oesophageal reflux disease. Br J Clin Pharmacol. 1999;48(5):688–93.PubMedPubMedCentralCrossRef

40.

Mirochnick M, Capparelli E, Connor J. Pharmacokinetics of zidovudine in infants: a population analysis across studies. Clin Pharmacol Ther. 1999;66(1):16–24.PubMedCrossRef

41.

Wang J, Liang WQ, Wu JJ, Pan CM. Population pharmacokinetic analysis of amikacin and validation on neonates using Monte Carlo method. Acta Pharmacol Sin. 2000;21(10):954–60.PubMed

42.

de Hoog M, Schoemaker RC, Mouton JW, van den Anker JN. Vancomycin population pharmacokinetics in neonates. Clin Pharmacol Ther. 2000;67(4):360–7.PubMedCrossRef

43.

Hansen TG, Ilett KF, Reid C, Lim SI, Hackett LP, Bergesio R. Caudal ropivacaine in infants: population pharmacokinetics and plasma concentrations. Anesthesiology. 2001;94(4):579–84.PubMedCrossRef

44.

Bleyzac N, Varnier V, Labaune JM, Corvaisier S, Maire P, Jelliffe RW, et al. Population pharmacokinetics of amikacin at birth and interindividual variability in renal maturation. Eur J Clin Pharmacol. 2001;57(6–7):499–504.PubMed

45.

Kimura T, Kokubun H, Nowatari M, Matsuura N, Sunakawa K, Kubo H. Population pharmacokinetics of panipenem in neonates and retrospective evaluation of dosage. J Antimicrob Chemother. 2001;47(1):51–9.PubMedCrossRef

46.

Falcão AC, Buelga DS, Méndez ME, García MJ, Pardo M. Population kinetics of tobramycin in neonates. Ther Drug Monit. 2001;23(3):202–8.PubMedCrossRef

47.

Capparelli EV, Lane JR, Romanowski GL, McFeely EJ, Murray W, Sousa P, et al. The influences of renal function and maturation on vancomycin elimination in newborns and infants. J Clin Pharmacol. 2001;41(9):927–34.PubMedCrossRef

48.

Tod M, Lokiec F, Bidault R, De Bony F, Petitjean O, Aujard Y. Pharmacokinetics of oral acyclovir in neonates and in infants: a population analysis. Antimicrob Agents Chemother. 2001;45(1):150–7.PubMedPubMedCentralCrossRef

49.

Suematsu F, Yukawa E, Yukawa M, Minemoto M, Ohdo S, Higuchi S, et al. Population-based investigation of relative clearance of digoxin in Japanese neonates and infants by multiple-trough screen analysis. Eur J Clin Pharmacol. 2001;57(1):19–24.PubMedCrossRef

50.

Stolk LM, Degraeuwe PL, Nieman FH, de Wolf MC, de Boer A. Population pharmacokinetics and relationship between demographic and clinical variables and pharmacokinetics of gentamicin in neonates. Ther Drug Monit. 2002;24(4):527–31.PubMedCrossRef

51.

de Hoog M, Schoemaker RC, van den Anker JN, Vinks AA. NONMEM and NPEM2 population modeling: a comparison using tobramycin data in neonates. Ther Drug Monit. 2002;24(3):359–65.PubMedCrossRef

52.

Odoul F, Le Guellec C, Henrot A, Saliba E, Levron JC, Saux MC, et al. Population pharmacokinetics of cisapride in neonates. Eur J Clin Pharmacol. 2002;58(8):507–13.PubMedCrossRef

53.

Mulla H, McCormack P, Lawson G, Firmin RK, Upton DR. Pharmacokinetics of midazolam in neonates undergoing extracorporeal membrane oxygenation. Anesthesiology. 2003;99(2):275–82.PubMedCrossRef

54.

Botha JH, du Preez MJ, Adhikari M. Population pharmacokinetics of gentamicin in South African newborns. Eur J Clin Pharmacol. 2003;59(10):755–9.PubMedCrossRef

55.

DiCenzo R, Forrest A, Slish JC, Cole C, Guillet R. A gentamicin pharmacokinetic population model and once-daily dosing algorithm for neonates. Pharmacotherapy. 2003;23(5):585–91.PubMedCrossRef

56.

Gregoire N, Gualano V, Geneteau A, Millerioux L, Brault M, Mignot A, et al. Population pharmacokinetics of ibuprofen enantiomers in very premature neonates. J Clin Pharmacol. 2004;44(10):1114–24.PubMedCrossRef

57.

Smyth JM, Collier PS, Darwish M, Millership JS, Halliday HL, Petersen S, et al. Intravenous indometacin in preterm infants with symptomatic patent ductus arteriosus: a population pharmacokinetic study. Br J Clin Pharmacol. 2004;58(3):249–58.PubMedPubMedCentralCrossRef

58.

Bouwmeester NJ, Anderson BJ, Tibboel D, Holford NH. Developmental pharmacokinetics of morphine and its metabolites in neonates, infants and young children. Br J Anaesth. 2004;92(2):208–17.PubMedCrossRef

59.

Rapp HJ, Molnár V, Austin S, Krohn S, Gädeke V, Motsch J, et al. Ropivacaine in neonates and infants: a population pharmacokinetic evaluation following single caudal block. Paediatr Anaesth. 2004;14(9):724–32.PubMedCrossRef

60.

Allegaert K, Anderson BJ, Naulaers G, de Hoon J, Verbesselt R, Debeer A, et al. Intravenous paracetamol (propacetamol) pharmacokinetics in term and preterm neonates. Eur J Clin Pharmacol. 2004;60(3):191–7.PubMedCrossRef

61.

Kimura T, Sunakawa K, Matsuura N, Kubo H, Shimada S, Yago K. Population pharmacokinetics of arbekacin, vancomycin, and panipenem in neonates. Antimicrob Agents Chemother. 2004;48(4):1159–67.PubMedPubMedCentralCrossRef

62.

Lanao JM, Calvo MV, Mesa JA, Martín-Suárez A, Carbajosa MT, Miguelez F, et al. Pharmacokinetic basis for the use of extended interval dosage regimens of gentamicin in neonates. J Antimicrob Chemother. 2004;54(1):193–8.PubMedCrossRef

63.

Bailey JM, Hoffman TM, Wessel DL, Nelson DP, Atz AM, Chang AC, et al. A population pharmacokinetic analysis of milrinone in pediatric patients after cardiac surgery. J Pharmacokinet Pharmacodyn. 2004;31(1):43–59.PubMedCrossRef

64.

Chalkiadis GA, Anderson BJ, Tay M, Bjorksten A, Kelly JJ. Pharmacokinetics of levobupivacaine after caudal epidural administration in infants less than 3 months of age. Br J Anaesth. 2005;95(4):524–9.PubMedCrossRef

65.

Fukuda T, Yukawa E, Kondo G, Maeda T, Shin-o T, Kondo Y, et al. Population pharmacokinetics of theophylline in very premature Japanese infants with apnoea. J Clin Pharm Ther. 2005;30(6):591–6.PubMedCrossRef

66.

Capparelli E, Hochwald C, Rasmussen M, Parham A, Bradley J, Moya F. Population pharmacokinetics of cefepime in the neonate. Antimicrob Agents Chemother. 2005;49(7):2760–6.PubMedPubMedCentralCrossRef

67.

Yukawa E, Suematsu F, Yukawa M, Minemoto M. Population pharmacokinetic investigation of phenobarbital by mixed effect modelling using routine clinical pharmacokinetic data in Japanese neonates and infants. J Clin Pharm Ther. 2005;30(2):159–63.PubMedCrossRef

68.

Würthwein G, Groll AH, Hempel G, Adler-Shohet FC, Lieberman JM, Walsh TJ. Population pharmacokinetics of amphotericin B lipid complex in neonates. Antimicrob Agents Chemother. 2005;49(12):5092–8.PubMedPubMedCentralCrossRef

69.

Pullen J, Stolk LM, Nieman FH, Degraeuwe PL, van Tiel FH, Zimmermann LJ. Population pharmacokinetics and dosing of amoxicillin in (pre)term neonates. Ther Drug Monit. 2006;28(2):226–31.PubMedCrossRef

70.

Pullen J, de Rozario L, Stolk LM, Degraeuwe PL, van Tiel FH, Zimmermann LJ. Population pharmacokinetics and dosing of flucloxacillin in preterm and term neonates. Ther Drug Monit. 2006;28(3):351–8.PubMedCrossRef

71.

García B, Barcia E, Pérez F, Molina IT. Population pharmacokinetics of gentamicin in premature newborns. J Antimicrob Chemother. 2006;58(2):372–9.PubMedCrossRef

72.

Al Z’aabi M, Lanner A, Xiaonian X, Donovan T, Charles B. Application of routine monitoring data for determination of the population pharmacokinetics and enteral bioavailability of phenytoin in neonates and infants with seizures. Ther Drug Monit. 2006;28(6):793–9.CrossRef

73.

Zuppa AF, Nicolson SC, Adamson PC, Wernovsky G, Mondick JT, Burnham N, et al. Population pharmacokinetics of milrinone in neonates with hypoplastic left heart syndrome undergoing stage I reconstruction. Anesth Analg. 2006;102(4):1062–9.PubMedCrossRef

74.

van Kesteren C, Benders MJ, Groenendaal F, van Bel F, Ververs FF, Rademaker CM. Population pharmacokinetics of allopurinol in full-term neonates with perinatal asphyxia. Ther Drug Monit. 2006;28(3):339–44.PubMedCrossRef

75.

Al Za’abi M, Donovan T, Tudehope D, Woodgate P, Collie LA, Charles B. Orogastric and intravenous indomethacin administration to very premature neonates with patent ductus arteriosus: population pharmacokinetics, absolute bioavailability, and treatment outcome. Ther Drug Monit. 2007;29(6):807–14.PubMedCrossRef

76.

Allegaert K, Peeters MY, Verbesselt R, Tibboel D, Naulaers G, de Hoon JN, et al. Inter-individual variability in propofol pharmacokinetics in preterm and term neonates. Br J Anaesth. 2007;99(6):864–70.PubMedCrossRef

77.

Muller AE, DeJongh J, Bult Y, Goessens WH, Mouton JW, Danhof M, et al. Pharmacokinetics of penicillin G in infants with a gestational age of less than 32 weeks. Antimicrob Agents Chemother. 2007;51(10):3720–5.PubMedPubMedCentralCrossRef

78.

Anderson BJ, Allegaert K, Van den Anker JN, Cossey V, Holford NH. Vancomycin pharmacokinetics in preterm neonates and the prediction of adult clearance. Br J Clin Pharmacol. 2007;63(1):75–84.PubMedCrossRef

79.

Acosta EP, Brundage RC, King JR, Sánchez PJ, Sood S, Agrawal V, National Institute of Allergy and Infectious Diseases Collaborative Antiviral Study Group, et al. Ganciclovir population pharmacokinetics in neonates following intravenous administration of ganciclovir and oral administration of a liquid valganciclovir formulation. Clin Pharmacol Ther. 2007;81(6):867–72.PubMedCrossRef

80.

Yukawa E, Akiyama K, Suematsu F, Yukawa M, Minemoto M. Population pharmacokinetic investigation of digoxin in Japanese neonates. J Clin Pharm Ther. 2007;32(4):381–6.PubMedCrossRef

81.

Paradisis M, Jiang X, McLachlan AJ, Evans N, Kluckow M, Osborn D. Population pharmacokinetics and dosing regimen design of milrinone in preterm infants. Arch Dis Child Fetal Neonatal Ed. 2007;92(3):F204–9.PubMedCrossRef

82.

Hirt D, Van Overmeire B, Treluyer JM, Langhendries JP, Marguglio A, Eisinger MJ, et al. An optimized ibuprofen dosing scheme for preterm neonates with patent ductus arteriosus, based on a population pharmacokinetic and pharmacodynamic study. Br J Clin Pharmacol. 2008;65(5):629–36.PubMedPubMedCentralCrossRef

83.

Gregoire N, Desfrere L, Roze JC, Kibleur Y, Koehne P. Population pharmacokinetic analysis of Ibuprofen enantiomers in preterm newborn infants. J Clin Pharmacol. 2008;48(12):1460–8.PubMedCrossRef

84.

Palmer GM, Atkins M, Anderson BJ, Smith KR, Culnane TJ, McNally CM, et al. I.V. acetaminophen pharmacokinetics in neonates after multiple doses. Br J Anaesth. 2008;101(4):523–30.PubMedCrossRef

85.

Lima-Rogel V, Medina-Rojas EL, Del Carmen Milán-Segovia R, Noyola DE, Nieto-Aguirre K, López-Delarosa A, et al. Population pharmacokinetics of cefepime in neonates with severe nosocomial infections. J Clin Pharm Ther. 2008;33(3):295–306.PubMedCrossRef

86.

Bradley JS, Sauberan JB, Ambrose PG, Bhavnani SM, Rasmussen MR, Capparelli EV. Meropenem pharmacokinetics, pharmacodynamics, and Monte Carlo simulation in the neonate. Pediatr Infect Dis J. 2008;27(9):794–9.PubMedCrossRef

87.

Wade KC, Wu D, Kaufman DA, Ward RM, Benjamin DK Jr. Sullivan JE, et al. National Institute of Child Health and Development Pediatric Pharmacology Research Unit Network. Population pharmacokinetics of fluconazole in young infants. Antimicrob Agents Chemother. 2008;52(11):4043–9.PubMedPubMedCentralCrossRef

88.

Charles BG, Townsend SR, Steer PA, Flenady VJ, Gray PH, Shearman A. Caffeine citrate treatment for extremely premature infants with apnea: population pharmacokinetics, absolute bioavailability, and implications for therapeutic drug monitoring. Ther Drug Monit. 2008;30(6):709–16.PubMedCrossRef

89.

Dailly E, Drouineau MH, Gournay V, Rozé JC, Jolliet P. Population pharmacokinetics of domperidone in preterm neonates. Eur J Clin Pharmacol. 2008;64(12):1197–200.PubMedCrossRef

90.

Zuppa AF, Mondick JT, Davis L, Cohen D. Population pharmacokinetics of ketorolac in neonates and young infants. Am J Ther. 2009;16(2):143–6.PubMedCrossRef

91.

Sherwin CM, Svahn S, Van der Linden A, Broadbent RS, Medlicott NJ, Reith DM. Individualised dosing of amikacin in neonates: a pharmacokinetic/pharmacodynamic analysis. Eur J Clin Pharmacol. 2009;65(7):705–13.PubMedCrossRef

92.

Nielsen EI, Sandström M, Honoré PH, Ewald U, Friberg LE. Developmental pharmacokinetics of gentamicin in preterm and term neonates: population modelling of a prospective study. Clin Pharmacokinet. 2009;48(4):253–63.PubMedCrossRef

93.

van den Anker JN, Pokorna P, Kinzig-Schippers M, Martinkova J, de Groot R, Drusano GL, et al. Meropenem pharmacokinetics in the newborn. Antimicrob Agents Chemother. 2009;53(9):3871–9.PubMedPubMedCentralCrossRef

94.

Mukherjee A, Dombi T, Wittke B, Lalonde R. Population pharmacokinetics of sildenafil in term neonates: evidence of rapid maturation of metabolic clearance in the early postnatal period. Clin Pharmacol Ther. 2009;85(1):56–63.PubMedCrossRef

95.

Hirt D, Urien S, Rey E, Arrivé E, Ekouévi DK, Coffié P, et al. Population pharmacokinetics of emtricitabine in human immunodeficiency virus type 1-infected pregnant women and their neonates. Antimicrob Agents Chemother. 2009;53(3):1067–73.PubMedCrossRef

96.

Hirt D, Urien S, Ekouévi DK, Rey E, Arrivé E, Blanche S, et al. ANRS 12109. Population pharmacokinetics of tenofovir in HIV-1-infected pregnant women and their neonates (ANRS 12109). Clin Pharmacol Ther. 2009;85(2):182–9.PubMedCrossRef

97.

Ahsman MJ, Hanekamp M, Wildschut ED, Tibboel D, Mathot RA. Population pharmacokinetics of midazolam and its metabolites during venoarterial extracorporeal membrane oxygenation in neonates. Clin Pharmacokinet. 2010;49(6):407–19.PubMedCrossRef

98.

Marqués-Miñana MR, Saadeddin A, Peris JE. Population pharmacokinetic analysis of vancomycin in neonates: a new proposal of initial dosage guideline. Br J Clin Pharmacol. 2010;70(5):713–20.PubMedPubMedCentralCrossRef

99.

Lo YL, van Hasselt JG, Heng SC, Lim CT, Lee TC, Charles BG. Population pharmacokinetics of vancomycin in premature Malaysian neonates: identification of predictors for dosing determination. Antimicrob Agents Chemother. 2010;54(6):2626–32.PubMedPubMedCentralCrossRef

100.

Hope WW, Smith PB, Arrieta A, Buell DN, Roy M, Kaibara A, et al. Population pharmacokinetics of micafungin in neonates and young infants. Antimicrob Agents Chemother. 2010;54(6):2633–7.PubMedPubMedCentralCrossRef

101.

Blumer J, Rodriguez A, Sánchez PJ, Sallas W, Kaiser G, Hamed K. Single-dose pharmacokinetics of famciclovir in infants and population pharmacokinetic analysis in infants and children. Antimicrob Agents Chemother. 2010;54(5):2032–41.PubMedPubMedCentralCrossRef

102.

Xie HG, Cao YJ, Gauda EB, Agthe AG, Hendrix CW, Lee H. Clonidine clearance matures rapidly during the early postnatal period: a population pharmacokinetic analysis in newborns with neonatal abstinence syndrome. J Clin Pharmacol. 2011;51(4):502–11.PubMedCrossRef

103.

Ward RM, Tammara B, Sullivan SE, Stewart DL, Rath N, Meng X, et al. Single-dose, multiple-dose, and population pharmacokinetics of pantoprazole in neonates and preterm infants with a clinical diagnosis of gastroesophageal reflux disease (GERD). Eur J Clin Pharmacol. 2010;66(6):555–61.PubMedCrossRef

104.

Benaboud S, Ekouévi DK, Urien S, Rey E, Arrivé E, Blanche S, TEmAA ANRS 12109 Study Group, et al. Population pharmacokinetics of nevirapine in HIV-1-infected pregnant women and their neonates. Antimicrob Agents Chemother. 2011;55(1):331–7.PubMedCrossRef

105.

Kearns GL, Reed MD. Clinical pharmacokinetics in infants and children: a reappraisal. Clin Pharmacokinet. 1989;17:29–67.PubMedCrossRef

106.

Anderson BJ, Allegaert K, Holford NH. Population clinical pharmacology of children: modelling covariate effects. Eur J Pediatr. 2006;165:819–29.PubMedCrossRef

107.

West GB, Brown JH, Enquist BJ. The fourth dimension of life: fractal geometry and allometric scaling of organisms. Science. 1999;284(5420):1677–9.PubMedCrossRef

108.

Anderson BJ, Holford NH. Mechanistic basic of using body size and maturation to predict clearance in humans. Drug Metab Pharmacokinet. 2009;24(1):25–36.PubMedCrossRef

109.

Rhodin MM, Anderson BJ, Peters AM, Coulthard MG, Cole M, Chatelut E, et al. Human renal function maturation: a quantitative description using weight and postmenstrual age. Pediatr Nephrol. 2009;24(1):67–76.PubMedCrossRef

110.

World Health Organization. WHO model lists of essential medicines. http://whqlibdoc.who.int/hq/2011/a95964_fre.pdf. Accessed 1 Oct 2010.

111.

Jacqz-Aigrain E, Burtin P. Clinical pharmacokinetics of sedatives in neonates. Clin Pharmacokinet. 1996;31(6):423–43.PubMedCrossRef

112.

Rennie JM, Boylan GB. Neonatal seizures and their treatment. Curr Opin Neurol. 2003;6(2):177–81.CrossRef

113.

Painter MJ, Pippenger C, Wasterlain C, Barmada M, Pitlick W, Carter G, Abern S. Phenobarbital and phenytoin in neonatal seizures: metabolism and tissue distribution. Neurology. 1981;31(9):1107–12.PubMedCrossRef

114.

Tokola RA, Neuvonen PJ. Pharmacokinetics of antiepileptic drugs. Acta Neurol Scand Suppl. 1983;97:17–27.PubMedCrossRef

Title: Population Pharmacokinetic Analysis during the First 2 Years of Life
An Overview
Authors: Amélie Marsot
Audrey Boulamery
Bernard Bruguerolle
Nicolas Simon
Publication date: 01-12-2012
Publisher: Springer International Publishing
Published in: Clinical Pharmacokinetics / Issue 12/2012
Print ISSN: 0312-5963
Electronic ISSN: 1179-1926
DOI: https://doi.org/10.1007/s40262-012-0015-8

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Population Pharmacokinetic Analysis during the First 2 Years of Life

An Overview

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 12/2012

Inter-Individual Differences in Baseline Coagulation Activities and Their Implications for International Normalized Ratio Control During Warfarin Initiation Therapy

Erratum to: Comparative Clinical Pharmacokinetics of Dipeptidyl Peptidase-4 Inhibitors

Pharmacokinetic, Pharmacodynamic and Covariate Analysis of Subcutaneous Versus Intravenous Administration of Bortezomib in Patients with Relapsed Multiple Myeloma

Acknowledgement

Pharmacodynamic Models for Discrete Data

Pharmacokinetic Modelling of Efavirenz, Atazanavir, Lamivudine and Tenofovir in the Female Genital Tract of HIV-Infected Pre-Menopausal Women